Why China-Based Gracell Biotechnologies (GRCL) Stock Is Soaring Today

AstraZeneca Plc AZN has agreed to acquire Gracell Biotechnologies Inc GRCL, further strengthening AstraZeneca's cell therapy portfolio. The deal value is $2.00/share (equivalent to $10/ADS ADS of Gracell) plus a non-tradable contingent value right of $0.30/share (equivalent to $1.50/ADS of…#astrazenecaplcazn #astrazeneca #gracell #bcma #susangalbraith
Source: Reuters: Health - Category: Consumer Health News Source Type: news